Nandita Puchakayala, MD
Psychiatry · Chino, CANPI 1720320989
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,955 of the $77,385 with a category attached, or 64.6%. 28 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 41.0% of the total. 2025 is the largest year on record at $49,202, more than ten times the $1,061 reported in 2019. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 518 payments — averaging $149.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$32K
- Axsome Therapeutics, Inc.$19K
- Janssen Scientific Affairs, LLC$14K
- AbbVie$6K
- Johnson & Johnson$2K
- Otsuka America Pharmaceutical, Inc.$1K
- plus $4K from 22 others
Across 9 payments — averaging $3564.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$22K
- Bristol Myers Squibb$10K
- AbbVie$589
What the payments were for
- Consulting fees$13,62518%
- Speaking & faculty fees$49,95565%
- Travel & lodging$2,4973%
- Food & beverage$11,12714%
- Education$1800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 98 | $31,693 |
| Axsome Therapeutics, Inc. | 32 | $19,094 |
| Janssen Scientific Affairs, LLC | 3 | $13,735 |
| AbbVie(2 entities) | 60 | $5,551 |
| Johnson & Johnson | 60 | $1,817 |
| Otsuka America Pharmaceutical, Inc. | 59 | $1,247 |
| Neurocrine Biosciences, Inc. | 33 | $1,138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 44 | $696 |
| Lundbeck LLC | 31 | $472 |
| Indivior Inc. | 16 | $361 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $337 |
| Supernus Pharmaceuticals, Inc. | 14 | $279 |
| Alkermes, Inc. | 11 | $251 |
| Vanda Pharmaceuticals Inc. | 12 | $213 |
| E.r. Squibb & Sons, L.L.C. | 12 | $204 |
| Tris Pharma Inc | 3 | $45 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| Noven Therapeutics, LLC | 1 | $25 |
| Shire North American Group Inc | 1 | $24 |
| Ironshore Pharmaceuticals Inc. | 1 | $22 |
| Novo Nordisk | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $21 |
| Bausch Health US, LLC | 1 | $20 |
| Corium, LLC | 1 | $19 |
| Almatica Pharma LLC | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Brainsway USA Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$29,983
- Auvelity$18,516
- SPRAVATO$13,727
- INVEGA SUSTENNA$13,727
- VRAYLAR$4,500
- INGREZZA$444
- TRINTELLIX$113
How this compares
$77,385 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 23 | $149,119 |
| IngrezzaValbenazine Tosylate | 11 | $89,994 |
| VraylarCariprazine Hcl | 49 | $70,823 |
| Invega SustennaPaliperidone Palmitate | 11 | $32,997 |
| Abilify MaintenaAripiprazole | 12 | $32,799 |
| TrintellixVortioxetine Hydrobromide | 39 | $27,215 |
| UzedyRisperidone | 11 | $20,416 |
| Aripiprazole | 112 | $17,472 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $14,227 |
| Quetiapine Fumarate | 311 | $7,113 |
| Divalproex Sodium ErDivalproex Sodium | 36 | $2,154 |
| Bupropion XlBupropion Hcl | 102 | $1,708 |
| Trazodone Hcl | 212 | $1,574 |
| Duloxetine Hcl | 71 | $1,493 |
| Olanzapine | 89 | $1,419 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $31,693 | $169,53534 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,138 | $89,99411 claims |
| AbbVieVraylar | $5,551 | $70,82349 claims |
| Johnson & JohnsonInvega Sustenna | $1,817 | $32,99711 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,247 | $32,79912 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $696 | $27,21539 claims |
| Axsome Therapeutics, Inc.Auvelity | $19,094 | $14,22712 claims |
| Almatica Pharma LLCSertraline Hcl | $18 | $933123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Chino
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.